ProBioGen to spearhead GMP manufacturing at Berlin’s gene & cell therapy hub

ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit

Meissa Vaccines enters into CGMP manufacturing agreement for pediatric RSV vaccine candidate for Phase 2 clinical trials

Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials

ProBioGen partners with Granite Bio for cell line development and GMP manufacturing services

Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B

Vaccizone selects Exothera for GMP manufacturing of its SARS?CoV?2 vaccine

Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells

Neuland Labs and LIR Life partner on next-gen transdermal GLP-1 obesity therapy platform

LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity

Local manufacturing, deeper CDMO ties, region-specific solutions remain our top priorities in next 3–5 years: Ganesh Bade, Head Bioprocessing, India, Avantor

Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region

Clean Cells, Naobios step up Asia expansion at BIO KOREA 2026 in Seoul

The event marks a significant push into South Korea’s rapidly expanding bio-health ecosystem

RoosterBio taps MineBio to supercharge hMSC & exosome solutions in China

HRV Pharma, Shodhana join hands to build next-gen API pipeline for global markets

Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets

Torqur taps Lonza to power late-stage push for skin cancer therapy

Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds